Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quest PharmaTech Inc.

www.questpharmatech.com

Latest From Quest PharmaTech Inc.

Pipeline Watch: Kisqali, SI-6603, Cosentyx Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Immuno-Oncology Outlook: Bavencio Leads PD-1/L1 Pack In Ovarian Cancer

Merck KGaA/Pfizer's Bavencio is likely to be the first checkpoint inhibitor to gain approval in ovarian cancer but Roche's Tecentriq is hot on its heels. The ovarian cancer pipeline boasts seven other late-stage drugs, including antibody-drug conjugates and small molecules, that are ready to ramp up competition on the market.

Clinical Trials ImmunoOncology

Pipeline Watch: Phase III Starts With Simvastatin, AR101 And Brexanolone

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Latest R&D Deal Builds China Antibody Interest, Expertise

To promote both the development of innovative therapeutic antibodies from research originating in China and technology transfer, the Institute Pasteur of Shanghai and MRC Technology are collaborating to speed antibody R&D and scouting licensing opportunities with local pharmas, adding to a string of deals indicative of China’s increasing expertise and interest in the sector.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Altachem Pharma Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Quest PharmaTech Inc.
  • Senior Management
  • Madi Madiyalakan, PhD, CEO
    Pierre Vermette, CFO
    Thomas Woo, VP, Prod. Dev.
  • Contact Info
  • Quest PharmaTech Inc.
    Phone: (780) 448-1400
    8123 Roper Rd. NW
    Edmonton, T6E 6S4
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register